Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

证券代码：603786 证券简称：科博达 公告编号：2025-085 科博达技术股份有限公司 第三届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 为增强全资子公司 KEBODA Deutschland GmbH & Co. KG（科博达德国两合 公司）的资金实力和运营能力，同意公司使用自有资金 2,120 万欧元对科博达德 国两合公司增资，增资完成后科博达德国两合公司的注册资本为 5,127.5 万欧元。 详见同日披露的《科博达技术股份有限公司关于对全资子公司增资的公告》 （公告编号：2025-087）。 科博达技术股份有限公司（以下简称"公司"）第三届董事会第二十三次会 议通知于 2025 年 12 月 2 日以邮件方式发出，并于 2025 年 12 月 12 日上午 10:00 时以现场会议结合通讯表决方式召开。会议应出席董事 9 名，亲自出席董事 9 名（董事陈耿先生、独立董事孙林先生以通讯方式参加了会议），公司部分高级 管理人员列席了会议，会议由董事长柯桂华先生主 ...

科博达技术股份有限公司 关于对全资子公司增资的公告 证券代码：603786 证券简称：科博达 公告编号：2025-087 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称： KEBODA Deutschland GmbH & Co. KG（科博达德国 两合公司，以下简称"德国科博达"） 投资金额：2,120 万欧元（约 17,395.024 万元人民币） 交易实施尚需履行的审批及其他相关程序 本次增资事项已经科博达技术股份有限公司（以下简称"公司"）第三届董 事会第二十三次会议审议通过，无需提交公司股东会审议。 其它需要提醒投资者重点关注的风险事项 本次增资对象为公司的全资子公司，整体风险可控，但仍受宏观经济、行业 环境、市场竞争、经营管理等因素的影响，经营状况和收益存在不确定性的风险。 公司将加强对全资子公司的运营管控，确保其合规、稳健、高效经营，提高资金 使用效率，加强风险管控，力争取得良好的投资回报。敬请广大投资者注意投资 风险。 一、对外投资概述 （一）本次交易概况 1、本次交易概况 二、投 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 关于补选审计委员会委员的公告 证券代码：603786 证券简称：科博达 公告编号：2025-086 科博达技术股份有限公司 科博达技术股份有限公司董事会 陈耿，男，中国国籍，无境外永久居留权，1968 年出生，博士学历，中 国 注册会计师。曾任深圳证券交易所上市部总经理、国泰君安证券股份有限公司 总 裁、副董事长等职务；现任杭州浙民投实业有限公司执行董事兼总经理、银联商 务支付股份有限公司董事等职务；2017 年 6 月至今，任公司董事。 2、许敏先生简历 许敏，男，美国国籍，中国永久居留权，1962 年出生，博士学历，教授。 历任通用汽车公司德尔福分部发动机管理系统研发部资深项目工程师、伟世通公 司研发中心发动机燃烧高级技术专家、奇瑞汽车有限公司副总经理兼汽车工程研 究院院长、上海交通大学校长助理；现任上海维骋汽车技术有限公司执行董事、 合肥常青机械股份有限公司独立董事等职务；2023 年 5 月至今，任公司董事。 2025 年 12 月 13 日 附件：简历 1、陈耿先生简历 ...

证券代码：603786 证券简称：科博达 公告编号：2025-088 科博达技术股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | | 被担保人名称 | 上海科博达智能科技有限公司（以 下简称"科博达智能科技"） | | | | --- | --- | --- | --- | --- | --- | | 担 | 保 对 | 本次担保金额 | 20,000 | 万元 | | | 象 | | 实际为其提供的担保余额 | 44,000 万元（含本次） | | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | 本次担保是否有反担保 | 是 | □否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 | 138,600 | | 子公司对外担保总额（万元） | | | 对外担保总额 ...

科博达（603786）(603786.SH)发布公告，为强化德国科博达征信能力，优化其财务结构，进一步保障 公司海外市场，提升公司全球化营运能力，拟使用自有资金对德国科博达增资2,120万欧元，增资完成 后德国科博达的注册资本5,127.5万欧元，仍为公司的全资子公司。 ...

智通财经APP讯， 科博达(603786.SH)发布公告，为强化德国科博达征信能力，优化其财务结构，进一 步保障公司海外市场，提升公司全球化营运能力，拟使用自有资金对德国科博达增资2,120万欧元，增 资完成后德国科博达的注册资本5,127.5万欧元，仍为公司的全资子公司。 ...

Investment Rating - The report does not explicitly state an investment rating for the automotive suspension industry Core Insights - The automotive suspension industry is undergoing a profound transformation driven by electrification and intelligence, shifting the competitive focus from traditional mechanical hardware to a comprehensive system capability defined by software [4] - The demand for lightweight structural components and high-performance suspensions is increasing due to electrification, while intelligence is pushing the evolution of suspensions from passive adaptation to active prediction [4] - The value distribution across the entire industry chain will be redefined in this technological revolution, with investment opportunities focusing on leading domestic component manufacturers, system integrators with advantages in electric control suspensions, and suppliers providing key enabling technologies for intelligent suspensions [4] Summary by Sections Industry Overview - The automotive suspension system connects the vehicle body to the wheels, playing a crucial role in cushioning road impacts and ensuring good contact between the wheels and the ground [5] - The industry can be categorized into passive, semi-active, and active suspensions based on their working principles and application scenarios [5][6] Industry Characteristics - High-end market core technology barriers are significant, with foreign companies having established a "patent moat" in core suspension technologies [8] - Electrification is driving technological iterations, with new energy vehicles imposing stricter requirements on suspension systems [9] - Intelligent technology is enabling the transition of suspension systems from mechanical passive modes to electronically controlled active modes [10] Development History - The automotive suspension system has evolved from passive systems in the 1930s to semi-active systems in the 1970s, and to active systems gaining traction in the 1990s [11][12][13][14][15] Industry Chain Analysis - The automotive suspension industry chain consists of upstream (core materials and components), midstream (system design and assembly), and downstream (vehicle application and aftermarket services) [16] - The upstream component supply segment is highly concentrated, dominated by international suppliers like ZF and Continental [17][22] - Midstream, system integrators are increasingly investing in R&D to enhance differentiation and supply chain security [18][19] Market Size and Growth - The automotive suspension market size is projected to grow from 67.25 billion RMB in 2019 to 83.42 billion RMB in 2024, with a compound annual growth rate (CAGR) of 4.40% [29] - The market is expected to further expand to 111.45 billion RMB by 2029, with a CAGR of 6.10% [29] Future Trends - The demand for high-performance suspension systems is increasing, with technology being downscaled to mid-range markets [32] - The rise of line-controlled suspension systems is anticipated to support the development of automotive intelligence [33] Competitive Landscape - The competitive landscape is characterized by a "global leaders and Chinese tiered catch-up" scenario, with high market concentration [39] - Chinese manufacturers are rapidly closing the technology gap with international giants, driven by the growth of the new energy vehicle market [43][44]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603786 证券简称：科博达 公告编号：2025-084 科博达技术股份有限公司 关于2025年第三季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 科博达技术股份有限公司（以下简称"公司"） 2025年第三季度业绩说明会于2025年12月5日15:00- 16:00，在上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/）以网络互动的方式召 开，就投资者关注的问题在信息披露允许的范围内进行了交流。现将有关事项公告如下： 一、本次说明会召开情况 公司于2025年11月28日在上海证券交易所网站（www.sse.com.cn）及指定媒体披露了《科博达技术股份 有限公司关于召开2025年第三季度业绩说明会的预告公告》（公告编号：2025-081）。 回复：投资者您好，2025年前三季度，公司前五大终端客户合计贡献营收占比61.30%，其他客户营收 占比为38.70%。具体而言，前五大终端客户包括德 ...

科博达技术股份有限公司 关于 2025 年第三季度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 科博达技术股份有限公司（以下简称"公司"） 2025 年第三季度业绩说明会 于 2025 年 12 月 5 日 15:00-16:00，在上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/）以网络互动的方式召开，就投资者关注的问题在信 息披露允许的范围内进行了交流。现将有关事项公告如下： 一、本次说明会召开情况 公司于 2025 年 11 月 28 日在上海证券交易所网站（www.sse.com.cn）及指 定媒体披露了《科博达技术股份有限公司关于召开 2025 年第三季度业绩说明会 的预告公告》（公告编号：2025-081）。 2025 年 12 月 5 日，公司董事长兼总裁柯桂华先生、董事会秘书赵泽元先生、 财务负责人朱迎春女士、独立董事孙林先生出席了本次说明会，与投资者进行了 互动交流和沟通，就投资者关注的问题进行了回复。 证券代码：603786 证 ...